REG - Avacta Group PLC - Notice of Results and Investor Presentation

AvactaAnnouncement

30/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220330:nRSd4599Ga&default-theme=true

RNS Number : 4599G  Avacta Group PLC  30 March 2022

 

30 March 2022

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Notice of Results and Investor Presentation

 

Avacta Group plc (AIM: AVCT), a clinical stage oncology company and developer
of powerful diagnostics based on its innovative Affimer(®) and pre|CISION™
platforms, will announce its financial results for the year ended 31 December
2021 on Wednesday, 6 April 2022.

 

Investor webinar

An investor webinar presentation by Alastair Smith, Chief Executive Officer
and Tony Gardiner, Chief Financial Officer will take place at 11:00am BST on
Wednesday, 6 April 2022.

 

The webinar is open to all existing and potential investors and will consist
of a presentation followed by a Q&A session, held on the Investor Meet
Company platform. Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9am the day before the meeting or at any time
during the live presentation.

 

Investors can sign up to Investor Meet Company for free and then click "Add to
meet" Avacta Group via the following link to join the webinar:

 

https://www.investormeetcompany.com/avacta-group-plc/register-investor
(https://www.investormeetcompany.com/avacta-group-plc/register-investor)

 

Investors who already follow Avacta Group plc on the Investor Meet Company
platform will automatically be invited.

 

The Company will also post its results presentation on its website at the
following page: https://avacta.com/investors/documents-presentations
(https://avacta.com/investors/documents-presentations)

 

 

ENDS

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                              Tel: +44 (0) 844 414 0452

 Alastair Smith, Chief Executive Officer                       www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Broker)             Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Fred Walsh / Nicholas Harland   www.stifel.com (http://www.stifel.com/)

 FTI Consulting (Financial Media and IR)                       Tel: +44(0) 203 727 1000

 Simon Conway / Alex Shaw                                      Avacta.LS@fticonsulting.com (mailto:Avacta.LS@fticonsulting.com)

 Zyme Communications (Trade and Regional Media)                Tel: +44 (0)7891 477 378

 Lily Jeffery                                                  lily.jeffery@zymecommunications.com

                                                             (mailto:katie.odgaard@zymecommunications.com)

 

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com)

 

Avacta Group is developing novel cancer immunotherapies and powerful
diagnostics based on its two proprietary platforms - Affimer(®) biologics and
pre|CISION™ tumour targeted chemotherapies.

 

The Affimer(®) platform is an alternative to antibodies and is derived from a
small human protein. Affimer technology has been designed to address many of
the negative issues of antibodies, principally: the time taken to generate new
antibodies, the reliance on an animal's immune response; poor specificity in
many cases; in addition to, the complexity and high cost of manufacture.
Despite these shortcomings, antibodies currently dominate markets, such as
diagnostics and therapeutics, which are worth in excess of $100bn.

 

Avacta's pre|CISION™ targeted chemotherapy platform is designed to
selectively release active chemotherapy in FAP rich tumour tissue to limit the
systemic exposure that causes damage to healthy tissues, and thereby aims to
improve the overall safety and therapeutic potential of these powerful
anti-cancer treatments.

 

The Avacta Group comprises two divisions: The therapeutics development
activities are based in London and Cambridge, UK and a separate diagnostics
business unit is based in Wetherby, UK. The Group is generating near-term
revenues from Affimer(®) reagents for diagnostics, bioprocessing and
research.

 

Avacta's Diagnostics Division is developing an in-house pipeline of
Affimer-based diagnostic assays, including the AffiDX(®) SARS-CoV-2 Lateral
Flow Rapid Antigen Test, and works with partners world-wide to develop bespoke
Affimer(®) reagents for third party products.

 

Avacta's Therapeutics Division is working to generate more tolerable and
durable treatments for oncology patients who do not respond to existing
therapies. By combining its two proprietary platforms the Group is building a
wholly owned pipeline of clinically differentiated cancer therapies. In 2021
Avacta transitioned to become a clinical stage biopharmaceutical company, when
it commenced a phase I trial in patients with locally advanced or metastatic
selected solid tumours. The study was a first-in-human, open label,
dose-escalation and expansion study of the Group's lead pre|CISION™ prodrug,
AVA6000 (a pro-doxorubicin).

 

Avacta has established drug development partnerships with pharma and biotech,
including a multi-target deal with LG Chem worth up to $400m, a joint venture
in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies
incorporating Affimer immune-modulators and a recent license agreement with
Point Biopharma for them to develop radiopharmaceuticals based on the
pre|CISION™ platform.

 

To register for news alerts by email go
to www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREAKDNADAAEFA